CDC42 and cancer: The Rac/Cdc42 downstream effector group I PAKs (PAKs 1–3) are direct downstream effectors of Rac and Cdc42 that have been the subject of intense investigation for targeted anticancer drugs due to their central role in cancer progression to metastasis (39–42).